HOUSTON, Sept. 8, 2025 /PRNewswire/ -- AAVivo, Inc., a pioneering biotechnology developing novel, precision targeted biotherapeutics to enable in vivo generation of CAR-T cells, today announced that ...

Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes Kits incorporate Thermo Fisher Scientific’s CaptureSelect affinity reagents for ...

CHARLESTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular ...

PITTSBURGH, Jan. 9, 2026 /PRNewswire/ -- Avista Therapeutics, a preclinical gene therapy company built on deep clinical, computational and gene therapy expertise, today announced the significant ...

PHILADELPHIA, PA — Latus Bio, Inc. unveiled a significant expansion of its artificial intelligence and machine learning program as the company pushes deeper into AI-driven AAV capsid and payload ...

AMSTERDAM & BOSTON & SEATTLE--(BUSINESS WIRE)--VectorY Therapeutics, a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, and ...

VectorY Therapeutics has signed an agreement securing an exclusive option to assess Shape Therapeutics’ SHP-DB1 adeno-associated virus (AAV) capsid for vectorised antibody payloads targeting three ...

Solid Biosciences signed a gene therapy agreement with CDMO Andelyn Biosciences for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101. Solid grants Andelyn a non-exclusive worldwide ...

Reliable quantification of total AAV capsid concentration is key to maintaining consistency and supporting informed decision-making. The integration of Thermo Fisher Scientific's CaptureSelect ...

The AAV9 Total Capsid Quantification Kit incorporates CaptureSelect Anti-AAV9 Biotin and HRP Conjugates for focused quantification of AAV9 particles. Dr Ruizhi Wang, CEO and Founder, Abselion, said: ...